GrifolsGRFS +0.48%84 PS Ratio is 0.58 as of Jun. 27, 2026, which is 81% below its 10-year median of 3.09. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Grifols ranks better than 79.01% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Grifols's share price is $7.39.
Grifols's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $12.68. Hence, Grifols's PS Ratio for today is 0.58.
Good Sign:
Grifols SA stock PS Ratio (=0.84) is close to 1-year low of 0.79.
The historical rank and industry rank for Grifols's PS Ratio or its related term are showing as below:
GRFS'
s PS Ratio Range Over the Past 10 Years
Min: 0.74 Med: 3.09 Max: 8.2
Current: 0.84
During the past 13 years, Grifols's highest PS Ratio was 8.20. The lowest was 0.74. And the median was 3.09.
GRFS's PS Ratio is ranked better than 79.01% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs GRFS: 0.84
Grifols's Revenue per Sharefor the
three
months ended in Mar. 2026 was $2.89.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $12.68.
Warning Sign:
Grifols SA revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Grifols was 2.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 7.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.00% per year.
During the past 13 years, Grifols's highest 3-Year average Revenue per Share Growth Rate was 51.60% per year. The lowest was -5.60% per year. And the median was 7.80% per year.
Back to Basics: PS Ratio
Grifols (NAS:GRFS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Grifols PS Ratio Related Terms
Grifols PS Ratio Historical Data
* Premium members only.
The historical data trend for Grifols's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Grifols's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's PS Ratio distribution charts can be found below:
* The bar in red indicates where Grifols's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Grifols's Share Price of today is $7.39. Grifols's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Grifols (GRFS) has a PS Ratio of 0.58 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Grifols and its competitors. This is 81% below median its historical median of 3.09. Over the past decade, Grifols' PS Ratio has ranged from 0.74 to 8.20. According to the industry distribution chart, Grifols ranks #200 out of 953 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Grifols' PS Ratio too high?
Grifols' current PS Ratio of 0.58 is 81% below median its 10-year median of 3.09. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 8.20. The Drug Manufacturers industry median PS Ratio is 2.20. Grifols' value of 0.58 is 73.6% below this industry median. Based on the distribution chart, Grifols ranks #200 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #200 out of 953 companies for PS Ratio. This places Grifols in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.20. Grifols' value of 0.58 is 73.6% below this benchmark. Historically, Grifols' own PS Ratio has ranged from 0.74 to 8.20 over the past decade. While the company's 10-year median is 3.09 vs. the industry median of 2.20, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current PS Ratio of 0.58 is 73.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current PS Ratio is 0.58, which is 81% below median its own 10-year median of 3.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.87, compared to a current price of $7.39 — trading 16.7% below its estimated fair value. The current PS Ratio is 0.58, which is 81% below median its 10-year median of 3.09 and 73.6% below the Drug Manufacturers industry median of 2.20. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Grifols (GRFS), the current PS Ratio is 0.58 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.39 is trading 16.7% below its estimated GF Value™ of $8.87.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
PS Ratio: 0.58 (81% below median its 10-year median of 3.09)
GF Value™: $8.87 vs. price of $7.39 (16.7% below fair value)
Industry Position: 73.6% below the Drug Manufacturers median (#200 of 953)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
